Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recentonset type 1 diabetes: A randomized double-blind trial

Hospital for Sick Children, University of Toronto, Toronto, ON, Canada (D K Wherrett MD); University of South Florida, Tampa, FL, USA (B Bundy PhD, Prof J P Krischer PhD); University of Pittsburgh, Pittsburgh, PA, USA (Prof D J Becker MD); Indiana University School of Medicine, Indianapolis, IN, USA (L A DiMeglio MD, Prof H Rodriguez MD); University of California San Francisco, San Francisco, CA, USA (Prof S E Gitelman MD); Columbia University, New York, NY, USA (Prof R Goland MD); University of Colorado Barbara Davis Center for Childhood Diabetes, Aurora, CO, USA (Prof P A Gottlieb MD); Benaroya Research Institute, Seattle, WA, USA (C J Greenbaum MD ); Yale University School of Medicine, New Haven, CT, USA (Prof K C Herold MD); Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA (Prof J B Marks MD, Prof J S Skyler MD); Children’s Hospital Los Angeles, Los Angeles, CA, USA (R Monzavi MD); University of Minnesota, Minneapolis, MN, USA (Prof A Moran MD); Joslin Diabetes Center, Boston, MA, USA (T Orban MD); University of Washington School of Medicine, Seattle, WA, USA (J P Palmer MD); University of Texas Southwestern Medical School, Dallas, TX, USA (Prof P Raskin MD); University of Florida, Gainesville, FL, USA (Prof D Schatz MD); and Stanford University, Stanford, CA, USA (Prof D M Wilson MD) Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial